Bioavailability of resveratrol

Annals of the New York Academy of Sciences

Volumn 1215, Issue 1, 2011, Pages 9-15

  Walle, Thomas ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Bioavailability; Metabolism; Resveratrol

Indexed keywords

3',4',5',5,7 PENTAMETHOXYFLAVONE; 3,4,5,4' TETRAMETHOXYSTILBENE; BACTERIAL ENZYME; BETA GLUCURONIDASE; DRUG ANALOG; GLUCURONIDE; PTEROSTILBENE; RESVERATROL; SULFATASE; SULFATE; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL METABOLISM; CHEMOPROPHYLAXIS; COLON CANCER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SULFATION; DRUG TRANSPORT; HUMAN; IN VIVO STUDY; INTESTINE; LIVER; NEOPLASM; PLASMA CONCENTRATION-TIME CURVE; SINGLE DRUG DOSE;

BACTERIA (MICROORGANISMS);

EID: 78851469101     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05842.x     Document Type: Article

References (42)

1. Baur, J.A. & D.A. Sinclair 2006. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. 5: 493-506.
2. Gescher, A.J. & W.P. Steward 2003. Relationship between mechanisms, bioavailability, and preclinical chemopreventive efficacy of resveratrol: a conundrum. Cancer Epidemiol. Biomark. Prev. 12: 953-957.
3. Goldberg, D.M., J. Yan & G.J. Soleas 2003. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin. Biochem. 36: 79-87.
4. Walle, T., F. Hsieh, M.H. DeLegge, et al 2004. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 32: 1377-1382.
5. Artursson, P. & J. Karlsson 1991. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun. 175: 880-885.
6. Kaldas, M.I., U.K. Walle & T. Walle 2003. Resveratrol transport and metabolism by human intestinal Caco-2 cells. J. Pharm. Pharmacol. 55: 307-312.
7. Maier-Salamon, A., B. Hagenauer, G. Reznicek, et al 2008. Metabolism and disposition of resveratrol in the isolated perfused rat liver: role of Mrp2 in the biliary excretion of glucuronides. J. Pharm. Sci. 97: 1615-1628.
8. van der Wetering, K., A. Burkon, W. Feddema, et al 2009. Intestinal breast cancer resistance protein (BCRP)/Bcpr1 and multidrug resistance protein 3 (MRP3)/Mrp3 are involved in the pharmacokinetics of resveratrol. Mol. Pharmacol. 75: 876-885.
9. Boocock, D.J., G.E.S. Faust, K.R. Patel, et al 2007. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol. Biomark. Prev. 16: 1246-1252.
10. Almeida, L., M. Vaz-da-Silva, A. Falcão, et al 2009. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol. Nutr. Food Res. 53: S7-S15.
11. Tessitore, L., A. Davit, I. Sarotto, et al 2000. Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21CIP expression. Carcinogenesis 21: 1619-1622.
12. Li, Z.G., T. Hong, Y. Shimada, et al 2002. Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by resveratrol. Carcinogenesis 23: 1531-1536.
13. Banerjee, S., C. Bueso-Ramos & B.B. Aggarwal 2002. Suppression of 7, 12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-κB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res. 62: 4945-4954.
14. Learmonth, D.A. 2003. A concise synthesis of the 3-O-β-D- and 4'-O-β-D-glucuronide conjugates of trans-resveratrol. Bioconjugate Chem. 14: 262-267.
15. Yu, C., Y.G. Shin, A. Chow, et al 2002. Human, rat, and mouse metabolism of resveratrol. Pharm. Res. 19: 1907-1914.
16. Miksits, M., A. Maier-Salamon, S. Aust, et al 2005. Sulfation of resveratrol in human liver: evidence of a major role for the sulfotransferases SULT1A1 and SULT1E1. Xenobiotica 35: 1101-1119.
17. Hoshino, J., E.-J. Park, T.P. Kondratyuk, et al 2010. Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J. Med. Chem. 53: 5033-5043.
18. Murias, M., M. Miksits, S. Aust, et al 2008. Metabolism of resveratrol in breast cancer cell lines: impact of sulftransferase 1A1 expression on cell growth inhibition. Cancer Lett. 261: 172-182.
19. Otake, Y., A.L. Nolan, U.K. Walle, et al 2000. Quercetin and resveratrol potently reduce estrogen sulfotransferase in normal human mammary epithelial cells. J. Steroid Biochem. Mol. Biol. 73: 265-270.
20. Wang, D., T. Hang, C. Wu, et al 2005. Identification of the major metabolites of resveratrol in rat urine by HPLC-MS/MS. J. Chromatogr. B. 829: 97-106.
21. Juan, M.E., I. Alfaras & J.M. Planas 2010. Determination of dihydroresveratrol in rat plasma by HPLC. J. Agric. Food Chem. 58: 7472-7475.
22. Jung, C.M., T.M. Heinze, L.K. Schnackenberg, et al 2009. Interaction of dietary resveratrol with animal-associated bacteria. FEMS Microbiol. Lett. 297: 266-273.
23. Stivala, L.A., M. Savio, F. Carafoli, et al 2001. Specific structural determinants are responsible for the antioxidant activity and the cell cycle effects of resveratrol. J. Biol. Chem. 276: 22586-22594.
24. Gakh, A.A., N.Y. Anisimova, M.V. Kiselevsky, et al 2010. Dihydro-resveratrol-a potent dietary polyphenol. Bioorg. Med. Chem. Lett. 20: 6149-6151.
25. van der Woude, H., A. Gliszczynska-Swiglo, K. Struijs, et al 2003. Biphasic modulation of cell proliferation by quercetin at concentrations physiologically relevant in humans. Cancer Lett. 200: 41-47.
26. Frankenfeld, C.L., A. McTiernan, E.J. Aiello, et al 2004. Mammographic density in relation to daidzein-metabolizing phenotypes in overweight, postmenopausal women. Cancer Epidemiol. Biomark. Prev. 13: 1156-1162.
27. Woting, A., T. Clavel, G. Loh, et al 2010. Bacterial transformation of dietary lignans in gnotobiotic rats. FEMS Microbiol. Ecol. 72: 507-514.
28. Miksits, M., K. Wicek, M. Svoboda, et al 2009. Antitumor activity of resveratrol and its sulfated metabolites against human breast cancer cells. Planta Med. 75: 1227-1230.
29. Burkon, A. & V. Somoza 2008. Quantitation of free and protein-bound trans-resveratrol metabolites and identification of trans-resveratrol-C/O-conjugated diglucuronides-two novel resveratrol metabolites in human plasma. Mol. Nutr. Food Res. 52: 549-557.
30. Lu, Z., Y. Zhang, H. Liu, et al 2007. Transport of a cancer chemopreventive polyphenol, resveratrol: interaction with serum albumin and hemoglobin. J. Fluoresc. 17: 580-587.
31. Bertelli, A.A.E., L. Giovanni, R. Stradi, et al 1996. Kinetics of trans- and cis-resveratrol (3, 4', 5-trihydroxystilbene) after red wine oral administration in rats. Int. J. Clin. Pharm. Res. 16: 77-81.
32. 3H]trans-resveratrol in rat tissues following oral administration. Br. J. Nutr. 96: 62-70.
33. Juan, M.E., M. Maijo & J.M. Planas 2010. Quantitation of trans-resveratrol and its metabolites in rat plasma and tissues by HPLC. J. Pharmaceut. Biomed. Anal. 51: 391-398.
34. 14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. Life Sci. 72: 2219-2233.
35. Sale, S., R.D. Verschoyle, D. Boocock, et al 2004. Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analoguetrans 3, 4, 5, 4'-tetramethoxystilbene. Br. J. Cancer. 90: 736-744.
36. Walle, T., U.K. Walle, D. Sedmera, et al 2006. Benzo[a]pyrene-induced oral carcinogenesis and chemoprevention-studies in bioengineered human tissue. Drug Metab. Dispos. 34: 346-350.
37. Suh, N., S. Paul, X. Hao, et al 2007. Pterostilbene, an active constituent of blueberries, suppresses aberrant crypt foci formation in the azomethane-induced colon carcinogenesis model in rats. Clin. Cancer Res. 13: 350-355.
38. Lin, H.-S., B.-D. Yue & P.C. Ho 2009. Determination of pterostilbene in rat plasma by a simple HPLC-UV method and its application in pre-clinical pharmacokinetic study. Biomed. Chromatogr. 23: 1308-1315.
39. Lin, H.-S. & P.C. Ho 2009. A rapid HPLC method for the quantification of 3, 5, 4'-trimethoxy-trans-stilbene (TMS) in rat plasma and its application in pharmacokinetic study. J. Pharm. Biomed. Anal. 49: 387-392.
40. Cai, H., S. Sale, R.G. Britton, et al 2010. Pharmacokinetics in mice and metabolism in murine and human liver fractions of the putative cancer chemopreventive agents 3', 4', 5', 5, 7-pentamethoxyflavone and tricin (4', 5, 7-trihydroxy-3', 5'-dimethoxyflavone). Cancer Chemother. Pharm. 2010 April 04 [Epub ahead of print] doi:.
41. Walle, T., X. Wen & U.K. Walle 2007. Improving metabolic stability of cancer chemopreventive polyphenols. Expert Op. Drug Metab. Toxicol. 3: 379-388.
42. Aumont, V., S. Krisa, E. Battaglia, et al 2001. Regioselective and stereospecific glucuronidation of trans- and cis-resveratrol in human. Arch. Biochem. Biophys. 393: 281-289.